Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00520806 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure
A Phase 2 study of Heart Failure, Congestive, sponsored by Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,161
- Enrollment target
- 3
- Study locations
NCT00520806 is a Phase 2 study of Heart Failure, Congestive that has completed, run by Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies. The registered enrollment target is 1,161 participants, above the 607-participant average among 33 other Heart Failure, Congestive trials with a reported enrollment target (91% higher). The trial reports 3 study locations across 3 states.
The verdict
NCT00520806, a Phase 2 study of Heart Failure, Congestive, has completed, sponsored by Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,161 participants
- Enrollment target
- 3
- Study locations
Study Summary
Different doses of relaxin will be compared to placebo to determine efficacy and safety for the treatment of patients hospitalized with acute heart failure
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Relaxin
Study Locations (3)
Illinois
- Northwestern University - Chicago
Michigan
- Wayne State University/Detroit Receiving Hospital - Detroit
Other
- Heart Institute - Safed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,161 participants |
| Start Date | 2007-10 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Sponsor
Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies1 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00520806
The ClinicalTrials.gov registry entry for NCT00520806 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,161 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 607-participant average among 33 other Heart Failure, Congestive trials with a reported enrollment target (91% higher). The listed sponsor is Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure, Congestive appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00520806 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Illinois, Michigan, Other.
Frequently Asked Questions
What is clinical trial NCT00520806 about?
NCT00520806 is a clinical study titled "Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure". Different doses of relaxin will be compared to placebo to determine efficacy and safety for the treatment of patients hospitalized with acute heart failure
What is the current status of trial NCT00520806?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,161 participants. The study started on 2007-10. Estimated completion is 2012-09.
What conditions does trial NCT00520806 study?
This clinical trial studies the following conditions: Heart Failure, Congestive.
What interventions are being tested in trial NCT00520806?
The interventions under investigation include: Placebo (DRUG), Relaxin (DRUG).
Who is sponsoring clinical trial NCT00520806?
This trial is sponsored by Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00520806 being conducted?
This trial has 3 study locations across Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure, Congestive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise After an ICD
COMPLETED · Phase 2
-
Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure
COMPLETED · Phase 2
-
Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).
COMPLETED · Phase 2
-
A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure
COMPLETED · Phase 2
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.